THERAPY DOSSIER · th-65d4691fb967

TLR4/MD-2 antagonist antibody

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04742062 ↗PHASE1completed

First in human dose ascending, randomised, placebo-controlled trial of ApTOLL (TLR4 antagonist) in healthy volunteers

Stroke

Enrolment: 46 · Results not recorded

NCT05293236 ↗PHASE1terminated

Double-blind, placebo-controlled, randomised Phase Ib study of ApTOLL for the treatment of COVID-19

COVID-19

Enrolment: 5 · Results not recorded

NCT05569720 ↗PHASE1completed

First in human trial comparing safety and tolerability of intravenous infusion vs bolus injection of ApTOLL in healthy volunteers

Stroke

Enrolment: 6 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21674704 ↗2010Reported benefit

Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis.

MouseChemical/toxinVillin-TLR4 transgenic

Model: DSS colitis and AOM-DSS colitis-associated tumorigenesis

A TLR4/MD-2 antagonist antibody inhibited colitis-associated neoplasia in mice, and constitutive epithelial TLR4 activation increased susceptibility to colitis and tumorigenesis.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…